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Chronic spontaneous urticaria (CSU) is a condition 
characterized by the recurrence of itchy wheals without 
any specific trigger for longer than 6 weeks (1). In CSU 
the wheals fluctuate throughout the day. Therefore, 
measurement of the activity of the disease and of the ef-
fectiveness of treatments is by means of patient-reported 
outcome (PRO) instruments, such as the Urticaria Ac-
tivity Score (UAS) (2). The UAS is a quantitative daily 
diary that includes a once-a-day (3) or twice-a-day (4) 
self-evaluation score. It is used for both clinical practice 
and trials to assess disease activity and treatment efficacy 
(1). Due to the chronicity and remarkable instability of 
CSU, daily UAS scores are summed over one week to 
create the UAS7 (3). However, there is a lack of infor-
mation on adherence to the instrument and the precision 
with which it is completed. The aim of this study was to 
evaluate adherence to the once-a-day UAS7 in real life, 
through an observational, descriptive, multicentre study 
on consecutive patients with CSU aged ≥18 years.
MATERIALS AND METHODS
All the patients were referred to 7 dermatology centres homoge-
neously distributed throughout north, central, and south Italy from 
January 2018 to December 2018. Demographic features including 
sex and age were recorded. All patients started antihistamine treat-
ment for 4 weeks and were asked to record disease activity for 4 
weeks using the once-a-day UAS7. The number of wheals and the 
intensity of pruritus were recorded and summed to create daily (0–
6) and weekly scores (0–42) (Table I). At the end of the 4th week, 
patients rated the simplicity and the effort required to complete 
the UAS7. For this purpose, a complementary questionnaire was 
used regarding 5 specific items about the completion of the UAS7: 
difficulty, boredom, time spent, disturbance of daily activities, and 
whether they felt better cared for. A 1–10 scale (1–3: negative, 
4–6: not sure, 7–10: positive) was used. Each patient completed 
the questionnaire anonymously and after the medical examination. 
At the same time, a designated dermatologist completed a 3-item 
questionnaire (yes or no) for each patient, regarding: (i) possible 
incompleteness; (ii) interruption of compilation; and (iii) calcula-
tion errors. The aim of this questionnaire was to evaluate whether 
the patient had correctly completed the UAS7 diary and to detect 
any possible errors. All parameters were analysed descriptively, 
using as-observed analysis. Mann–Whitney U test was used for 
between-group comparisons of continuous variables. Categorical 
variables were compared using Fisher’s exact test. A p-value < 0.01 
was considered indicative of statistical significance. The study was 
approved by the ethics committee of each centre, and informed 
consent was obtained prior to the interview.
RESULTS
A total of 129 consecutive CSU patients (mean ± standard 
deviation (SD) age 44.8 ± 16.3 years), mostly female 
(87/129; 67.4%) fulfilled the enrolment criteria and 
completed the study. The results of the 5-item questionn-
aire are reported in Table II. None of the results were 
statistically influenced by sex, age, geographical origin, 
baseline severity of disease, or response to treatment. 
Most patients reported that completing the UAS7 was 
not, or only minimally, difficult (score 1–3: 86.0%) or 
boring (score 1–3: 79.8%); the daily time spent to com-
plete it was sufficiently brief (score 1–3: 87.6%), and 
daily activities were not disturbed or conditioned (score 
1–3: 93.0%). In contrast, compilation of the UAS7 was 
reported as difficult (score 7–10: 4.7%) or boring (score 
7–10: 7.8%) only in rare cases and the daily time spent 
was rarely long (score 7–10: 1.6%). Only one patient 
(0.8%) reported that completing the questionnaire 
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Table I. Urticaria Activity Score (UAS) 
Score Number of wheals/24 h Pruritus
0 None None
1 < 20 Present but not annoying or troublesome
2 20–50 Troublesome but does not interfere with 




normal daily activity or sleep
Table II. Results of 5-item questionnaire administered in 129 
patients with chronic spontaneous urticaria (CSU) to evaluate 
criticisms of Urticaria Activity Score 7 (UAS7) from the patient’s 









Was it hard? 111 (86.0) 12 (9.3)   6 (4.7)
Was it boring? 103 (79.8) 16 (12.4) 10 (7.8)
Did you take a long time? 113 (87.6) 14 (10.8)   2 (1.6)
Did it disturb your daily activity? 120 (93.0)   8 (6.2)   1 (0.8)
Did it make you feel better taken 
care of by the dermatologist?
  26 (20.2) 23 (23.4) 80 (56.4)
a1–3: negative; 4–6: not bad not good; 7–10: positive. *Statistical differences 


























































significantly hindered daily activities (score 8). The 
differences found between the 3 scoring groups were 
significant (p < 0.00001) for all these items. Little more 
than half of the patients felt better taken care of by the 
dermatologist through UAS7 (score 7–10: 56.4%), while 
it was of little or no use (score 1–3) in 20.2% of patients. 
However, even in this case the difference was statistically 
significant (p < 0.00001). The designated dermatologist 
of each dermatology centre completed the 3-item for 
all the enrolled patients. At least one error was made 
in completing the UAS7 by 53/129 (41.1%) patients, 
41/53 (77.4%) incompletely completed the questionnaire, 
18/53 (34.0%) stopped compiling it before the 4-week 
deadline, and 11/53 (20.8%) made calculation mistakes. 
No significant differences were recorded regarding sex, 
geographical origin of the patients, baseline severity of 
CSU, or response to treatment. If the type and percentage 
of responses to the 5-item questionnaire are taken into 
consideration, no significant differences were found be-
tween the groups of patients who had correctly completed 
the questionnaire and those who had not. Most of the 
incomplete or interrupted UAS7 compilations occurred 
after the first week (84.6% and 88.2%, respectively). 
Patients who correctly compiled the UAS7 were younger 
than those who did not (42.0 vs. 48.7 years) (p = 0.01). 
Eleven patients, all from a single centre in southern Italy, 
were asked why they incompletely compiled (2 patients) 
or stopped compiling (9 patients) the questionnaire. 
Three reported that it was because they forgot and 8 
because they found the instrument useless (3/8) or more 
useful for the dermatologist than for themselves (5/8). 
DISCUSSION
In this study, adherence to once-a-day UAS7 for 4 weeks 
could not be univocally interpreted. The majority (on 
average more than 80%) of enrolled subjects found that 
completing the UAS7 was simple, not boring, did not 
take a long time, and did not disturb daily activities. 
Furthermore, 56.4% of patients had the distinct feeling 
of being better monitored by the dermatologist due to 
the UAS7, whereas 20.2% had the opposite feeling. On 
the other hand, the current study also shows that 41.1% 
of patients did not correctly complete the questionnaire, 
regardless of the opinion on the simplicity and effecti-
veness of the instrument. One explanation could be that 
difficulties in assessing itch and number of fluctuating 
wheals once daily could lead the patient to fail in drafting 
the questionnaire or to interrupt the recording (2). There-
fore, twice-a-day UAS (UASTD) (assessment every 12 
h) (4) has been introduced, although Hawro et al. (5) 
reported that both versions of the UAS show good and 
comparable clinometric properties and recommended 
the use of once-a-day UAS. Another possible explana-
tion could be that patients might consider completing 
the UAS7 to be more useful for the physician than for 
themselves, although these results are from a small group 
of 11 patients from a single centre. On the other hand, it 
is possible that, at least in some cases, the questionnaire 
was not well-described by the physician. It is therefore 
necessary for the patient to be well educated in using the 
questionnaire, in particular with regard to the importance 
of the tool for evaluating the effectiveness of the treat-
ment. Furthermore, it is worth noting that the degree of 
education of patients was not assessed. Considering that 
most mistakes and interruptions occurred after the first 
week, it is also possible that the use of this PRO instru-
ment for several weeks could have a negative effect on 
the patient’s adherence. However, completing the UAS7 
over a course of some weeks is essential for monitoring 
the disease and effectiveness of treatment. Evaluation for 
a longer period and on a larger sample of patients than 
those reported in this study would be necessary to better 
evaluate the adherence and the patients’ perspective. In 
this setting, an interesting and simpler method to assess 
the activity of CSU could be the Urticaria Activity and 
Impact Measure (U-AIM) (6). The U-AIM includes 9 
patient-reported items and is able retrospectively to as-
sess both activity and impact of the disease during the 
previous 7 days and does not require daily assessment. 
Indeed, unlike UAS7 U-AIM requires only one as-
sessment using patients’ recall and is also able to assess 
angioedema. Furthermore, the psychometric properties of 
the U-AIM have been demonstrated. On the other hand, 
it should be noted that the UAS7 is able to evaluate and 
document disease activity on a daily basis, helping the 
patients actively to address their disease and highlight 
any triggers. Further studies, comparing the patients’ 
perspective and adherence to the proposed PROs, should 
better delineate which is the best instrument for use in 
clinical practice.
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